Search Results - P. Ghia

Refine Results
  1. 1

    P597: HIGH DOSE IRON IMPAIRS MALIGNANT B-CELL VIABILITY IN CHRONIC LYMPHOCYTIC LEUKEMIA by J. Bordini, C. Lenzi, L. Toscani, P. Ranghetti, E. Perotta, L. Scarfò, P. Ghia, A. Campanella

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


  2. 2

    PB2362: BEST PRACTICES ON EMPOWERING AND INVOLVING PATIENTS LIVING WITH HEMATOLOGICAL MALIGNANCIES ON THE DEVELOPMENT OF NOVEL PATIENT-REPORTED OUTCOME MEASURES by N. Vrontaras, D. Kyrou, A. Kapetanakis, D. Tsakona, C. Karamanidou, L. Scarfò, P. Ghia, K. Stamatopoulos

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


  3. 3

    P616: THE LOSS OF IΚBΕ INHIBITOR ACCELERATES DISEASE DEVELOPMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA by C. Lenzi, J. Bordini, A. Pseftogkas, A. Morabito, G. Tsiolas, F. E. Psomopoulos, A. Campanella, M. Frenquelli, P. Ghia

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


  4. 4

    GENOMIC EVOLUTION AND RESISTANCE TO PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR PRE-TREATED CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: RESULTS FROM THE PHASE I/II BRUIN STUDY by JR Brown, JA Woyach, K Patel, TA Eyre, Cy Cheah, P Ghia, W Jurczak, P Abada, WG Wierda, GFPN Presenter

    Published in Hematology, Transfusion and Cell Therapy (2023-10-01)
    Get full text
    Article


  5. 5

    P667: LONG-TERM EFFICACY OF ACALABRUTINIB-BASED REGIMENS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND HIGHER-RISK GENOMIC FEATURES: POOLED ANALYSIS OF CLINICAL TRIAL DATA by M. Davids, J. Sharman, P. Ghia, J. Woyach, W. Jurczak, T. Siddiqi, P. Miranda, M. Shahkarami, T. Yu, U. Emeribe, J. Byrd

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


  6. 6

    P662: PATIENT-REPORTED OUTCOMES FROM A PHASE 3 RANDOMIZED STUDY OF ZANUBRUTINIB VERSUS BENDAMUSTINE PLUS RITUXIMAB (BR) IN PATIENTS WITH TREATMENT-NAÏVE (TN) CLL/SLL by P. Ghia, G. Barnes, K. Yang, C. Tam, P. Hillmen, T. Robak, J. Brown, B. Kahl, T. Tian, A. Szeto, J. Paik, M. Shadman

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


  7. 7

    C057 | SEQUOIA 5-YEAR FOLLOW-UP IN ARM C: FRONTLINE ZANUBRUTINIB MONOTHERAPY IN PATIENTS WITH DEL(17P) AND TREATMENT-NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA by A. Tedeschi, C.S. Tam, P. Ghia, M. Shadman, T. Munir, S.S. Opat, P.A. Walker, M. Lasica, I.W. Flinn, T. Tian, S. Agresti, J. Hirata, J.R. Brown

    Published in Haematologica (2025-09-01)
    Get full text
    Article


  8. 8

    PB1864: BRUIN CLL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR’S CHOICE OF IDELALISIB+RITUXIMAB OR BENDAMUSTINE+RITUXIMAB IN BTKI PRETREATED CLL/SLL... by J. P. Sharman, W. Jurczak, C. C. Coombs, M. Hill, D. Wang, N. C. Ku, A. Guntur, S. Shahda, C. C. Leow, P. Ghia, A. R. Mato

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


  9. 9

    PB2349: LESSONS LEARNED FROM THE MYPAL DIGITAL HEALTH INTERVENTION: CAPITALIZING ON THE PATIENT REPORTED OUTCOMES (PRO) PARADIGM TOWARDS A PARTICIPATORY HEALTHCARE FOR PATIENTS WIT... by C. Karamanidou, L. Scarfò, M. Doubek, S. Garani-Papadatos, J. Didi, C. Pontikoglou, E. Kazantzaki, J. Ling, C. Pain, H. Papadaki, R. Rosenquist, N. Stavroyianni, S. Payne, P. Ghia, K. Stamatopoulos, P. Natsiavas

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


  10. 10

    PB1878: CROSS-TRIAL ANALYSIS OF FIXED-DURATION IBRUTINIB (I) PLUS VENETOCLAX (V) VS FLUDARABINE (F), CYCLOPHOSPHAMIDE (C), AND RITUXIMAB (R) AS FIRST-LINE TREATMENT FOR CHRONIC LYM... by J. C. Barrientos, P. M. Barr, A. R. Mato, C. S. Tam, P. Ghia, C. Moreno, N. E. Kay, T. Siddiqi, E. Szafer-Glusman, C. Zhou, L. Neumayr, G. Krigsfeld, W. G. Wierda, T. Shanafelt

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


  11. 11

    B02 | SONROTOCLAX AND ZANUBRUTINIB AS FRONTLINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA DEMONSTRATES HIGH MINIMAL RESIDUAL DISEASE CLEARANCE RATES WITH GOOD TOLERABILITY: DATA F... by P. Ghia, J.D. Soumerai, C.Y. Cheah, M.A. Anderson, M. Lasica, E. Verner, S.S. Opat, S. Ma, R. Weinkove, R. Cordoba, S. Leitch, D. Westerman, S. Patel, Y. Fang, W. Ding, C.S. Tam

    Published in Haematologica (2025-09-01)
    Get full text
    Article


  12. 12

    P1463: PHASE I DOSE ESCALATION OF LAVA-051, A NOVEL BISPECIFIC GAMMA-DELTA T-CELL ENGAGER (GAMMABODY™), IN RELAPSED/REFRACTORY HEMATOLOGICAL MALIGNANCIES by A. Broijl, N. van de Donk, F. Bosch, M. V. Mateos, P. Rodriguez-Otero, A. Tucci, P. Ghia, A. Adang, P. Parren, I. Tuinhof, S. Umarale, B. Winograd, H. van der Vliet, A. Kater

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


  13. 13

    P593: MULTIDIMENSIONAL ANALYSIS OF THE B CELL RECEPTOR OFFERS INSIGHT INTO THE ONTOGENETIC RELATIONSHIP OF MONOCLONAL B-CELL LYMPHOCYTOSIS WITH CHRONIC LYMPHOCYTIC LEUKEMIA by A. Agathangelidis, C. Galigalidou, A. Iatrou, L. Zaragoza-Infante, L. Scarfò, M. C. Maniou, P. Ranghetti, N. Pechlivanis, V. Junet, A. Skaftason, M. Tsagiopoulou, F. Psomopoulos, R. Rosenquist, P. Ghia, A. Chatzidimitriou, K. Stamatopoulos

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


  14. 14

    DP006 | UPDATED SAFETY AND EFFICACY RESULTS OF A PHASE-1 STUDY OF THE NOVEL BCL2 INHIBITOR SONROTOCLAX (SONRO; BGB-11417) FOR RELAPSED/REFRACTORY WALDENSTRÖM MACROGLOBULINEMIA by L. Laurenti, C.Y. Cheah, C.S. Tam, R. García-Sanz, S. Leitch, E. Verner, R. Cordoba, M. Shadman, P. Ghia, F. Bosch, U. Hahn, M. Lasica, C. D’angelo, Y. Fang, W. Ding, C. Henrich, S. Patel, P. Browett

    Published in Haematologica (2025-09-01)
    Get full text
    Article


  15. 15

    P668: ACALABRUTINIB VS RITUXIMAB PLUS IDELALISIB OR BENDAMUSTINE IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: ASCEND RESULTS AT ~4 YEARS OF FOLLOW-UP by P. Ghia, A. Pluta, M. Wach, D. Lysak, M. Simkovic, I. Kriachok, A. Illes, J. de la Serna, S. Dolan, P. Campbell, G. Musuraca, A. Jacob, E. Avery, J. H. Lee, G. Usenko, M. H. Wang, T. Yu, W. Jurczak

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


  16. 16

    C056 | UPDATED EFFICACY/SAFETY OF THE BRUTON TYROSINE KINASE DEGRADER BGB-16673 IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA: RESULTS FROM THE ONG... by L. Scarfò, R.D. Parrondo, M.C. Thompson, A.M. Frustaci, J.N. Allan, P. Ghia, I. Mocanu, C.S. Tam, S. Stilgenbauer, D. Roos-Weil, J. Trotman, I. E. Ahn, N. Lamanna, L. Xu, K. By, S. Fabre, D. Persky, A. Agarwal, J. F. Seymour

    Published in Haematologica (2025-09-01)
    Get full text
    Article


  17. 17

    Conventional and non-conventional antigen-binding sites promote the development and function of chronic lymphocytic leukemia stereotyped subset #4 clones by Yun Liu, Yun Liu, Dzmitry Padhorny, Dzmitry Padhorny, Rosa Catera, Rosa Catera, Antonella Nicolo, Xiao-Jie Yan, Xiao-Jie Yan, Stan Xiaogang Li, Stan Xiaogang Li, Anastasia Iatrou, Andrea N. Mazzarello, Andrea N. Mazzarello, Noemi Destefani, Noemi Destefani, Steven L. Allen, Steven L. Allen, Jonathan E. Kolitz, Jonathan E. Kolitz, Kanti R. Rai, Kanti R. Rai, Massimo Degano, Massimo Degano, Paolo P. Ghia, Paolo P. Ghia, Charles C. Chu, Charles C. Chu, Florian Krammer, Florian Krammer, Hassan Jumaa, Kostas Stamatopoulos, Dima Kozakov, Dima Kozakov, Nicholas Chiorazzi, Nicholas Chiorazzi

    Published in Frontiers in Immunology (2025-08-01)
    Get full text
    Article


  18. 18

    P669: FIXED-DURATION (FD) IBRUTINIB + VENETOCLAX FOR FIRST-LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL): 3-YEAR FOLLOW-UP FROM THE PHASE 2... by C. Moreno, W. G. Wierda, P. M. Barr, T. Siddiqi, J. N. Allan, T. J. Kipps, L. Trentin, R. Jacobs, S. Jackson, A. Tedeschi, S. Opat, R. Bannerji, B. J. Kuss, L. J. Croner, E. Szafer-Glusman, C. Zhou, A. Szoke, J. P. Dean, P. Ghia, C. S. Tam

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


  19. 19

    C059 | PATIENT REPORTED OUTCOMES FROM BRUIN CLL-321: A RANDOMIZED PHASE 3 TRIAL COMPARING PIRTOBRUTINIB TO IDELALISIB/RITUXIMAB OR BENDAMUSTINE/RITUXIMAB IN COVALENT BTKI PRETREATE... by P. Ghia, D. Rossi, E. Ferrant, F. De La Cruz Vicente, D. Maruyama, V. Banerji, P. Cobb, S. Namburi, R. Greil, A. Loubert, K. Creel, L.M. Hess, N. Payakachat, A.S. Ruppert, D. Wang, P. Abada, C.C. Leow, M. Hill, C.C. Coombs, P. Barr, J.P. Sharman

    Published in Haematologica (2025-09-01)
    Get full text
    Article


  20. 20

    P666: ACALABRUTINIB ± OBINUTUZUMAB VS OBINUTUZUMAB + CHLORAMBUCIL IN TREATMENT-NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA: 5-YEAR FOLLOW-UP OF ELEVATE-TN by J. P. Sharman, M. Egyed, W. Jurczak, A. Skarbnik, K. Patel, I. W. Flinn, M. Kamdar, T. Munir, R. Walewska, L. M. Fogliatto, Y. Herishanu, V. Banerji, G. Follows, P. Walker, K. Karlsson, P. Ghia, A. Janssens, F. Cymbalista, E. Ferrant, W. G. Wierda, V. Munugalavadla, T. Yu, M. H. Wang, J. A. Woyach

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


Search Tools: